A novel high-throughput screening assay for sickle cell disease drug discovery

Journal of Biomolecular Screening

Volumn 14, Issue 4, 2009, Pages 330-336

  Pais, Eszter ^a,b   Cambridge, John S ^a   Johnson, Cage S ^a   Meiselman, Herbert J ^a   Fisher, Timothy C ^a   Alexy, Tamas ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Assay development; Cell based assay; Drug discovery; High throughput screening; Sickle cell disease

Indexed keywords

ANTISICKLING AGENT; ASPARTAME; PHENYLALANINE; POTASSIUM CYANATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ASSAY; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; ERYTHROCYTE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPRODUCIBILITY; ROBOTICS; SENSITIVITY AND SPECIFICITY; SICKLE CELL; SICKLE CELL ANEMIA;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BIOLOGICAL ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTES; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 65449132033     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109333975     Document Type: Article

References (26)

1. Flint J., Harding RM, Boyce AJ, Clegg JB: The population genetics of the haemoglobinopathies. Bailleres Clin Haematol 1993 ; 6: 215-262.
2. Pauling L., Itano HA, Singer SJ, Wells IC: Sickle cell anaemia, a molecular disease. Science 1949 ; 110: 543-548.
3. Brugnara C.: Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J Pediatr Hematol Oncol 2003 ; 25: 927-933.
4. Bunn HF: Induction of fetal hemoglobin in sickle cell disease. Blood 1999 ; 93: 1787-1789.
5. Cerami A., Manning JM: Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc Natl Acad Sci U S A 1971 ; 68: 1180-1183.
6. Charache S., Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995 ; 332: 1317-1322.
7. DeBellis RH, Chen B-X., Erlanger BF: Inhibition of sickling in vitro by three purine-based antiviral agents: an approach to the treatment of sickle cell disease. Blood Cells Mol Dis 2003 ; 31: 286-290.
8. Haley JD, Smith DE, Schwedes J., Brennan R., Pearce C., Moore C., et al. Identification and characterization of mechanistically distinct inducers of gamma-globin transcription. Biochem Pharmacol 2003 ; 66: 1755-1768.
9. Lee CK: Methylisocyanate as an antisickling agent and its reaction with hemoglobin S. J Biol Chem 1976 ; 251: 6226-6231.
10. Manion CV, Howard J., Ogle B., Parkhurst J., Edmundson A.: Aspartame effect in sickle cell anemia. Clin Pharmacol Ther 2001 ; 69: 346-355.
11. Noguchi CT, Luskey KL, Pavone V.: Dipeptides as inhibitors of the gelation of sickle hemoglobin. Mol Pharmacol 1985 ; 28: 40-44.
12. Ohnishi ST: Antisickling effects of membrane-interacting compounds. Blood Cells 1982 ; 8: 337-343.
13. Park S., Hayes BL, Marankan F., Mulhearn DC, Wanna L., Mesecar AD, et al. Regioselective covalent modification of hemoglobin in search of antisickling agents. J Med Chem 2003 ; 46: 936-953.
14. Reilly MP, Horiuchi K., Asakura T.: Dose-dependent red blood cell volume increase induced by bepridil. Gen Pharmacol 1993 ; 24: 1323-1329.
15. Hertzberg RB, Pope JP: High throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000 ; 4: 445-451.
16. Liu B., Li S., Hu J.: Technological advances in high-throughput screening. Am J Pharmacogenomics 2004 ; 4: 263-276.
17. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
18. Horiuchi K., Ohata J., Hirano Y., Asakura T.: Morphological studies of sick-led erythrocytes by image analysis. J Lab Clin Med 1990 ; 115: 613-620.
19. Horiuchi K., Stephens MJ, Adachi K., Asakura T., Schwartz E., Ohene-Frempong K.: Image analysis studies of the degree of irreversible deformation of sickle cells in relation to cell density and Hb F level. Br J Haematol 1993 ; 85: 356-364.
20. Ferrone FA, Hofrichter J., Eaton WA: Kinetics of sickle hemoglobin polymerization. I. Studies using temperature-jump and laser photolysis techniques. J Mol Biol 1985 ; 183: 591-610.
21. He Z., Russell JE: A high-throughput microplate method for assessing aggregation of deoxygenated hemoglobin S heterotetramers in vitro. Anal Biochem 2002 ; 306: 349-352.
22. Baerlocher GM, Meiselman HJ, Reinhart WH: Gel-filtration of sickle erythrocytes: separation based on cell deformability. Clin Hemorrheol Microcirc 2001 ; 24: 11-18.
23. Rohner F., Reinhart WH, Haeberli A., Straub PW: Gel filtration: a new method to analyze and separate red blood cells with different deform-abilities. J Lab Clin Med 1990 ; 116: 393-399.
24. Embury SH, Hebbel RP, Mohandas N., Steinberg MH: Sickle Cell Anemia: Basic Principles and Clinical Practice. New York: Raven Press, 1994.
25. Mozzarelli A., Hofrichter J., Eaton WA: Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 1987 ; 237: 500-506.
26. Hebbel RP: Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997 ; 99: 2561-2564.